GO:0015215 nucleotide transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015215 nucleotide transmembrane transporter activity describes the molecular function that enables the transfer of a nucleotide, a nucleoside esterified with orthophosphate, across a membrane.
• This activity is essential for nucleotide homeostasis, nucleic acid synthesis, and cellular energy metabolism, and is carried out by diverse membrane protein families including ABC transporters and P-type ATPases [1,3,4].
• ABC transporters such as ABCG2 and CFTR use nucleotide-binding domains (NBDs) to bind and hydrolyze ATP, coupling nucleotide transport to conformational changes [6,7].
• Single-nucleotide polymorphisms (SNPs) in transmembrane domains of ABC transporters can impair expression, membrane localization, and transport activity, linking this GO term to disease susceptibility [2,8].
• P-type ATPases like the Na,K-ATPase and the ER Mg2+ transporter ERMA (TMEM94) transport nucleotides or ions across membranes using ATP-driven phosphorylation cycles [3,4].
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of nucleotide transmembrane transporter genes in health and disease.
Description
Nucleotide transmembrane transporter activity (GO:0015215) is a molecular function that enables the movement of nucleotides, which are nucleosides esterified with orthophosphate, across biological membranes. This activity is fundamental to cellular nucleotide homeostasis, providing substrates for nucleic acid synthesis and energy transfer, and is mediated by specialized membrane proteins that couple transport to ATP binding and hydrolysis [1,6]. Researchers study this term to understand how cells import and export nucleotide derivatives, how mutations in transporter genes lead to disease, and how to target these proteins therapeutically [2,8]. The function is carried out by diverse protein families, including ATP-binding cassette (ABC) transporters and P-type ATPases, which share the ability to bind nucleotides and undergo conformational changes that move substrates across membranes [1,3,4]. ABC transporters such as ABCG2 and CFTR contain nucleotide-binding domains (NBDs) that bind and hydrolyze ATP, and mutations in these domains can abolish transport activity [6,7]. P-type ATPases, such as the Na,K-ATPase and the endoplasmic reticulum Mg2+ transporter ERMA (TMEM94), also use nucleotide binding and phosphorylation to drive transport [3,4]. Given its central role in nucleotide metabolism and membrane transport, GO:0015215 is a key term for understanding drug resistance, metabolic disorders, and genetic diseases [2,8].
nucleotide transmembrane transporter activity At A Glance
| GO ID | GO:0015215 |
|---|---|
| GO term | nucleotide transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Enables the transfer of a nucleotide from one side of a membrane to the other |
| Definition source | QuickGO |
| Related protein families | ABC transporters, P-type ATPases |
| Disease relevance | Cancer drug resistance, cystic fibrosis, metabolic disorders |
What Is GO:0015215?
According to the Gene Ontology, GO:0015215 nucleotide transmembrane transporter activity is defined as enabling the transfer of a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate, from one side of a membrane to the other. In other words, it is the molecular function of proteins that move nucleotide molecules across lipid bilayers, often using energy from ATP binding or hydrolysis to drive the transport process [1,6].
Why Is nucleotide transmembrane transporter activity Important in Cell Biology?
Nucleotide transmembrane transporter activity is critical for maintaining cellular nucleotide pools, which are required for DNA and RNA synthesis, energy currency (ATP/GTP), and signaling molecules (cAMP, cGMP). Dysregulation of this activity can lead to drug resistance in cancer cells, as seen with ABCG2, which exports nucleotide-based chemotherapeutics [2,8]. Moreover, mutations in transporters such as CFTR, which has nucleotide-binding domains, cause cystic fibrosis. Understanding this GO term helps researchers design targeted therapies and interpret genetic variants linked to disease [2,8].
• Maintains nucleotide homeostasis for nucleic acid synthesis and energy metabolism.
• Mediates cellular efflux of nucleotide-based drugs, contributing to multidrug resistance in cancer [2,8].
• Mutations in nucleotide-binding domains of CFTR cause cystic fibrosis.
• SNPs in transmembrane domains of ABCG2 impair transport activity and are linked to altered drug response [2,8].
• P-type ATPases such as Na,K-ATPase and ERMA use nucleotide binding to drive ion transport, affecting cellular signaling [3,4].
• Provides a target for modulating nucleotide-dependent processes in cancer and metabolic diseases [1,2].
• Essential for understanding membrane protein evolution and transport mechanisms [5,7].
• Facilitates the development of CRISPR models to study transporter gene function [2,8].
Mechanism, Genes and Research Methods
Nucleotide Binding and Recognition
In simple terms: The transporter first grabs the nucleotide molecule it needs to move.
Nucleotide transmembrane transporters typically contain nucleotide-binding domains (NBDs) that recognize and bind ATP or other nucleotides [6,7]. For ABC transporters, the NBDs form dimers that sandwich ATP, and this binding triggers conformational changes. In CFTR, the NBDs catalyze adenylate kinase activity rather than ATP hydrolysis, highlighting the diversity of nucleotide interactions. The specificity for nucleotides is determined by conserved motifs such as the Walker A and B motifs and the signature motif.
Conformational Changes and Substrate Translocation
In simple terms: After binding, the protein changes shape to push the nucleotide across the membrane.
Upon nucleotide binding, transporters undergo large-scale conformational changes that move the substrate across the lipid bilayer [1,5]. For ABC transporters, the transmembrane domains (TMDs) form a pathway that opens alternately to the two sides of the membrane. The energy from ATP binding and/or hydrolysis drives these changes, ensuring directional transport. In P-type ATPases, phosphorylation of the pump causes a similar shift in conformation.
Energy Coupling and ATP Hydrolysis
In simple terms: The protein uses ATP as an energy source to power transport.
Many nucleotide transporters are ATPases, meaning they hydrolyze ATP to ADP and phosphate to energize transport [1,4]. The Na,K-ATPase, for example, hydrolyzes ATP to pump ions against their gradients. In ABC transporters, ATP hydrolysis at the NBDs is coupled to substrate translocation through the TMDs [1,7]. However, some transporters, like CFTR, exhibit altered catalytic activity, catalyzing adenylate kinase activity instead of ATP hydrolysis.
Membrane Insertion and Assembly
In simple terms: The transporter must be correctly inserted into the membrane to work.
Nucleotide transporters are integral membrane proteins that require proper folding and insertion into the lipid bilayer [2,5]. Mutations in transmembrane domains can impair membrane localization, as shown for ABCG2 SNPs that reduce cell surface expression [2,8]. The assembly of multi-domain transporters, such as the bicomponent ABC transporter, involves channel formation by the transmembrane domain. Chaperones and quality control systems ensure correct folding.
Regulation by Nucleotides and Lipids
In simple terms: The activity of these transporters can be turned up or down by nucleotides and membrane lipids.
Nucleotide binding itself can regulate transporter activity, as seen in ABC transporters where ATP binding and hydrolysis cycle between states [1,7]. Lipids in the membrane can also modulate function, as ABC transporters are involved in lipid trafficking. Additionally, single-nucleotide polymorphisms can alter regulation, leading to impaired ATPase activity. The Na,K-ATPase is regulated by its nucleotide-binding site and by phosphorylation.
Key Genes Involved in GO:0015215 nucleotide transmembrane transporter activity
The following genes encode proteins that exhibit nucleotide transmembrane transporter activity or are directly involved in nucleotide transport across membranes, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCA1 | ABC transporter involved in lipid trafficking and nucleotide binding | Studied for cholesterol efflux and cardiovascular disease |
| ABCG2 | Multidrug transporter that exports nucleotide-based drugs | SNPs impair transport activity and drug resistance [2,8] |
| CFTR | ABC transporter with nucleotide-binding domains; chloride channel | Mutations cause cystic fibrosis; NBDs catalyze adenylate kinase activity |
| TMEM94 (ERMA) | P-type ATPase transporter for Mg2+ uptake in ER | Nucleotide-binding P-type ATPase; ER magnesium homeostasis |
| ATP1A1 | Na,K-ATPase alpha subunit; P-type ATPase | Nucleotide binding and ion transport; studied for cardiac and neurological disorders |
| ABCB1 | Multidrug resistance transporter; ABC family | Nucleotide-binding domains; drug efflux |
| ABCC7 | CFTR gene alias; ABC transporter | Nucleotide-binding domain function |
| SLC25A | Mitochondrial carrier family; nucleotide transport | Nucleotide transport across mitochondrial membrane |
| ENT1 (SLC29A1) | Equilibrative nucleoside transporter | Nucleotide and nucleoside transport; drug uptake |
| CNT (SLC28A) | Concentrative nucleoside transporter | Nucleotide transport; chemotherapy response |
| ABCG5 | ABC transporter; sterol transport | Nucleotide binding; lipid trafficking |
| ABCG8 | ABC transporter; sterol transport | Nucleotide binding; lipid trafficking |
| ABCA4 | ABC transporter; retinal transport | Nucleotide-binding domain; vision disorders |
| ABCB11 | Bile salt export pump; ABC transporter | Nucleotide binding; liver disease |
| ABCC1 | Multidrug resistance protein; ABC transporter | Nucleotide binding; drug resistance |
| ABCC2 | Multidrug resistance protein; ABC transporter | Nucleotide binding; drug transport |
| ABCC3 | Multidrug resistance protein; ABC transporter | Nucleotide binding; drug transport |
How Is nucleotide transmembrane transporter activity Regulated?
Nucleotide transmembrane transporter activity is regulated at multiple levels. Nucleotide binding itself modulates activity through conformational cycling, as seen in ABC transporters where ATP binding and hydrolysis alternate [1,7]. Phosphorylation regulates P-type ATPases such as the Na,K-ATPase. Single-nucleotide polymorphisms in transmembrane domains can impair expression and transport activity, as demonstrated for ABCG2 [2,8]. Additionally, membrane lipid composition influences transporter function, particularly for ABC transporters involved in lipid trafficking. The ER Mg2+ transporter ERMA (TMEM94) is regulated by its P-type ATPase cycle.
nucleotide transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCG2 | Multidrug resistance in cancer; impaired drug transport | Knockout and point-mutation models in cancer cell lines [2,8] |
| CFTR | Cystic fibrosis; defective chloride transport | Knock-in of patient mutations in airway epithelial cells |
| ATP1A1 | Cardiac arrhythmias; neurological disorders | Knockout and overexpression in cardiomyocytes |
| TMEM94 (ERMA) | ER magnesium homeostasis; metabolic disorders | Knockout in HEK293 cells |
| ABCB1 | Drug resistance in cancer | CRISPR knockout in leukemia cell lines |
Cancer Drug Resistance
ABC transporters such as ABCG2 and ABCB1 exhibit nucleotide transmembrane transporter activity and efflux chemotherapeutic drugs, contributing to multidrug resistance [2,8]. SNPs in ABCG2 that impair membrane localization and ATPase activity are associated with altered drug response in cancer patients [2,8]. Targeting these transporters is a major therapeutic strategy.
Cystic Fibrosis
Mutations in CFTR, an ABC transporter with nucleotide-binding domains, cause cystic fibrosis. The NBDs of CFTR catalyze adenylate kinase activity rather than ATP hydrolysis, and this altered nucleotide handling is linked to channel dysfunction. Understanding nucleotide interactions with CFTR is crucial for developing correctors and potentiators.
Metabolic and Neurological Disorders
The Na,K-ATPase (ATP1A1) uses nucleotide binding to transport ions and is implicated in cardiac and neurological disorders. The ER Mg2+ transporter ERMA (TMEM94) maintains magnesium homeostasis, and its dysfunction may affect metabolic processes. Nucleotide transporters in mitochondria influence energy metabolism and are linked to metabolic diseases.
From nucleotide transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ABCG2 increase drug sensitivity? | CRISPR knockout in cancer cell lines [2,8] |
| How do SNPs in ABCG2 affect transport activity? | Point-mutation knock-in in HEK293 cells [2,8] |
| Can wild-type CFTR restore chloride transport? | Knock-in of wild-type CFTR in CF patient cells |
| What is the role of TMEM94 in ER Mg2+ uptake? | Knockout and overexpression in HeLa cells |
| Does ATP1A1 overexpression alter ion homeostasis? | Overexpression in cardiac cells |
| Can tagged ABCG2 reveal localization dynamics? | Tagged knock-in in live cells |
How to Study the nucleotide transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled nucleotide transport assay | Direct transport of nucleotides across membranes | Characterizing transporter substrate specificity |
| ATPase activity assay | ATP hydrolysis rate | Measuring energy coupling in ABC transporters [4,6] |
| Immunofluorescence | Subcellular localization | Assessing membrane insertion of mutants [2,8] |
| CRISPR knockout screen | Gene essentiality and drug resistance | Identifying novel nucleotide transporters [2,8] |
| Patch-clamp electrophysiology | Ion channel activity | Studying CFTR chloride conductance |
| Surface biotinylation | Plasma membrane protein levels | Quantifying transporter surface expression |
| Bioinformatics pathway analysis | Enriched gene sets | Interpreting CRISPR screen hits |
| Structural modeling | Nucleotide-binding pocket interactions | Predicting mutation effects |
Transport Assays
Radiolabeled nucleotide uptake or efflux assays measure the direct transport activity of candidate transporters. For ABCG2, fluorescent substrates like mitoxantrone are used to assess efflux activity [2,8]. These assays are typically performed in membrane vesicles or intact cells.
ATPase Activity Assays
ATP hydrolysis can be measured using colorimetric or luminescent assays to determine if a transporter couples nucleotide binding to ATPase activity [4,6]. For CFTR, adenylate kinase activity is measured instead of ATP hydrolysis. These assays help distinguish functional NBDs.
Membrane Localization Studies
Immunofluorescence and cell surface biotinylation are used to assess whether transporters correctly localize to the plasma membrane [2,8]. Mutations that impair membrane insertion can be identified by comparing wild-type and mutant proteins.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes required for nucleotide transport or drug resistance [2,8]. Libraries targeting transporter genes can reveal synthetic lethal interactions. Bioinformatics analysis of screening data identifies enriched pathways.
How CRISPR Can Be Used to Study GO:0015215 nucleotide transmembrane transporter activity
Knockout
CRISPR knockout of nucleotide transporter genes such as ABCG2 or ATP1A1 can abolish transport activity, revealing their role in drug resistance or ion homeostasis [2,4]. Knockout cell lines are valuable for drug sensitivity assays.
Point Mutation
Introducing disease-associated SNPs, such as those in ABCG2 transmembrane domains, via CRISPR point mutation allows researchers to study impaired membrane localization and ATPase activity [2,8]. This approach mimics human genetic variants.
Knock-in
Knock-in of wild-type or mutant CFTR into patient-derived cells can restore or alter chloride transport, providing a model for cystic fibrosis. Tagged knock-in of transporters enables live-cell imaging.
Overexpression
Overexpression of nucleotide transporters like TMEM94 or ATP1A1 can enhance transport capacity and reveal gain-of-function phenotypes [3,4]. This is useful for biochemical assays requiring high protein levels.
How EDITGENE Supports nucleotide transmembrane transporter activity Research
Researchers studying nucleotide transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, drug resistance, or disease. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for nucleotide transmembrane transporter activity research.
Frequently Asked Questions About nucleotide transmembrane transporter activity
What is nucleotide transmembrane transporter activity?
It is a molecular function (GO:0015215) that enables the transfer of a nucleotide from one side of a membrane to the other, often using ATP binding or hydrolysis.
What genes are involved in nucleotide transmembrane transporter activity?
Genes include ABCG2, CFTR, ATP1A1, TMEM94, and many ABC transporters that bind and transport nucleotides [2,3,4,6].
How is nucleotide transmembrane transporter activity regulated?
It is regulated by nucleotide binding, phosphorylation, and membrane lipid composition, and can be impaired by single-nucleotide polymorphisms [1,2,4,8].
What diseases are associated with nucleotide transmembrane transporter activity?
Diseases include cancer drug resistance, cystic fibrosis, and metabolic disorders linked to mutations in transporters like ABCG2 and CFTR [2,6,8].
What methods are used to study nucleotide transmembrane transporter activity?
Methods include radiolabeled transport assays, ATPase activity assays, immunofluorescence, and CRISPR screens [1,2,4,6].
How can CRISPR be used to study nucleotide transporters?
CRISPR knockout, point mutation, knock-in, and overexpression models can reveal the causal role of transporter genes in disease and drug response [2,6,8].
What is the role of ABCG2 in nucleotide transport?
ABCG2 is an ABC transporter that exports nucleotide-based drugs; SNPs in its transmembrane domain impair its expression and transport activity [2,8].
How does CFTR relate to nucleotide transmembrane transporter activity?
CFTR is an ABC transporter with nucleotide-binding domains that catalyze adenylate kinase activity, and mutations cause cystic fibrosis.
What is the function of TMEM94 in nucleotide transport?
TMEM94 (ERMA) is a P-type ATPase that transports Mg2+ in the endoplasmic reticulum using nucleotide binding.
Why is nucleotide transmembrane transporter activity important for cancer?
It mediates efflux of chemotherapeutic drugs, leading to multidrug resistance, and is a target for overcoming resistance [1,2,8].
Conclusion
Nucleotide transmembrane transporter activity (GO:0015215) is a fundamental molecular function that governs the movement of nucleotides across membranes, impacting nucleic acid synthesis, energy metabolism, and drug resistance. Key transporters such as ABCG2, CFTR, and ATP1A1 have been extensively studied, revealing their roles in cancer, cystic fibrosis, and metabolic disorders [2,4,6,8]. CRISPR-based models are indispensable for dissecting the causal roles of these genes and for developing targeted therapies. EDITGENE provides a full suite of CRISPR services to support research on nucleotide transmembrane transporter activity.
References
- 1. Schmitz G et al.. 2000. ABC transporters in cellular lipid trafficking.. Curr Opin Lipidol 11(5):493-501 PMID: 11048892
- 2. Sjöstedt N et al.. 2017. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.. Pharm Res 34(8):1626-1636 PMID: 28281205
- 3. Vishnu N et al.. 2024. ERMA (TMEM94) is a P-type ATPase transporter for Mg(2+) uptake in the endoplasmic reticulum.. Mol Cell 84(7):1321-1337.e11 PMID: 38513662
- 4. Kaplan JH. 2002. Biochemistry of Na,K-ATPase.. Annu Rev Biochem 71:511-35 PMID: 12045105
- 5. Mohammad MM et al.. 2016. The Transmembrane Domain of a Bicomponent ABC Transporter Exhibits Channel-Forming Activity.. ACS Chem Biol 11(9):2506-18 PMID: 27379442
- 6. Gross CH et al.. 2006. Nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator, an ABC transporter, catalyze adenylate kinase activity but not ATP hydrolysis.. J Biol Chem 281(7):4058-68 PMID: 16361259
- 7. Ford RC et al.. 2020. What monomeric nucleotide binding domains can teach us about dimeric ABC proteins.. FEBS Lett 594(23):3857-3875 PMID: 32880928
- 8. Mizuarai S et al.. 2004. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.. Int J Cancer 109(2):238-46 PMID: 14750175
